TY  - JOUR
A1  - Mainz, Laura
A1  - Sarhan, Mohamed A. F. E.
A1  - Roth, Sabine
A1  - Sauer, Ursula
A1  - Maurus, Katja
A1  - Hartmann, Elena M.
A1  - Seibert, Helen-Desiree
A1  - Rosenwald, Andreas
A1  - Diefenbacher, Markus E.
A1  - Rosenfeldt, Mathias T.
T1  - Autophagy blockage reduces the incidence of pancreatic ductal adenocarcinoma in the context of mutant Trp53
JF  - Frontiers in Cell and Developmental Biology
N2  - Macroautophagy (hereafter referred to as autophagy) is a homeostatic process that preserves cellular integrity. In mice, autophagy regulates pancreatic ductal adenocarcinoma (PDAC) development in a manner dependent on the status of the tumor suppressor gene Trp53. Studies published so far have investigated the impact of autophagy blockage in tumors arising from Trp53-hemizygous or -homozygous tissue. In contrast, in human PDACs the tumor suppressor gene TP53 is mutated rather than allelically lost, and TP53 mutants retain pathobiological functions that differ from complete allelic loss. In order to better represent the patient situation, we have investigated PDAC development in a well-characterized genetically engineered mouse model (GEMM) of PDAC with mutant Trp53 (Trp53\(^{R172H}\)) and deletion of the essential autophagy gene Atg7. Autophagy blockage reduced PDAC incidence but had no impact on survival time in the subset of animals that formed a tumor. In the absence of Atg7, non-tumor-bearing mice reached a similar age as animals with malignant disease. However, the architecture of autophagy-deficient, tumor-free pancreata was effaced, normal acinar tissue was largely replaced with low-grade pancreatic intraepithelial neoplasias (PanINs) and insulin expressing islet β-cells were reduced. Our data add further complexity to the interplay between Atg7 inhibition and Trp53 status in tumorigenesis.
KW  - pancreatic cancer
KW  - autophagy
KW  - p53
KW  - metastasis
KW  - ATG7
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-266005
SN  - 2296-634X
VL  - 10
ER  - 
TY  - JOUR
A1  - Rosenfeldt, Mathias T.
A1  - Hartmann, Elena M.
A1  - Leng, Corinna
A1  - Rosenwald, Andreas
A1  - Anagnostopoulos, Ioannis
T1  - A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type
JF  - Annals of Hematology
N2  - No abstract available.
KW  - nodular lymphcyte
KW  - Hodgkin lymphoma
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232571
SN  - 0939-5555
VL  - 100
ER  - 
TY  - JOUR
A1  - Benkert, Thomas F.
A1  - Dietz, Lena
A1  - Hartmann, Elena M.
A1  - Leich, Ellen
A1  - Rosenwald, Andreas
A1  - Serfling, Edgar
A1  - Buttmann, Mathias
A1  - Berberich-Siebelt, Friederike
T1  - Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis
N2  - Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a serious adverse effect. Furthermore, drug cessation sometimes induces rebound disease activity of unknown etiology. Here we investigated whether binding of this adhesion-blocking antibody to T lymphocytes could modulate their phenotype by direct induction of intracellular signaling events. Primary CD4+ T lymphocytes either from healthy donors and treated with natalizumab in vitro or from MS patients receiving their very first dose of natalizumab were analyzed. Natalizumab induced a mild upregulation of IL-2, IFN-c and IL-17 expression in activated primary human CD4+ T cells propagated ex vivo from healthy donors, consistent with a pro-inflammatory costimulatory effect on lymphokine expression. Along with this, natalizumab binding triggered rapid MAPK/ERK phosphorylation. Furthermore, it decreased CD49d surface expression on effector cells within a few hours. Sustained CD49d downregulation could be attributed to integrin internalization and degradation. Importantly, also CD4+ T cells from some MS patients receiving their very first dose of natalizumab produced more IL-2, IFN-c and IL-17 already 24 h after infusion. Together these data indicate that in addition to its adhesion-blocking mode of action natalizumab possesses mild direct signaling capacities, which can support a pro-inflammatory phenotype of peripheral blood T lymphocytes. This might explain why a rebound of disease activity or IRIS is observed in some MS patients after natalizumab cessation.
KW  - Medizin
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-77905
ER  -